PATENT CLAIM ANALYSIS

Application Number: 16230090
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "246000"]

Abstract:
Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

Claim (Index 12):
The method of  claim 11 , wherein the acute myelogenous leukemia is relapsed or primary refractory.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 98.0
- Lexical Diversity: 1.13043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15548737', '15649551', '14909451', '14868283', '15612984']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8189357613545224
- 35 USC 102 Novelty (BERT): 0.5859752937563654
- Combined Prediction Score: 0.7956397145947067
- Mean Citation Score: 456.9320960000002
- Max Citation Score: 561.4229
- Similarity Product: 387.7122508601309

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test